Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Alpine Immune Sciences — Total liabilities by Quarter
Alpine Immune Sciences — Total liabilities ($M) ($M)
Vertex Pharmaceuticals Alpine Immune Sciences — Total liabilities: $40.9M in Q1 2024, down 55.8% from a year earlier. No newer figure appears in the documents we track.
Where the Q1 2024 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Alpine Immune Sciences — Total liabilities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2024 | Mar 31, 2024 | 40.9 | -55.8% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 51.9 | -51.6% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | 78.9 | -28.0% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 83.5 | -28.2% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 92.6 | -21.9% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 107 | -20.5% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | 110 | -1.0% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 116 | +0.3% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 119 | +54.6% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 135 | +64.8% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 111 | +27.8% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 116 | +34.1% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 76.7 | +206.8% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 81.9 | +232.8% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 86.6 | +189.4% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 86.5 | +250.5% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 25.0 | +137.5% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 24.6 | +139.5% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 29.9 | +214.2% | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 24.7 | +274.9% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 10.5 | +54.3% | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | 10.3 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | 9.52 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | 6.58 | – | SEC Filing ↗ |
| Q1 2018 | Mar 31, 2018 | 6.82 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences — Total liabilities ($M), quarterly Q1 2018–Q1 2024 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-liabilities
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.